MedTrace Logo

Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil

NCT03884465 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-09-13

No results posted yet for this study

Summary

Acute and chronic hemodynamic dose-response and safety evaluation of LIQ861 in PAH subjects.

Conditions

Interventions

DRUG

Inhaled dry powder treprostinil (LIQ861)

Inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg, or 100μg capsule strengths. Single dose in the acute setting. QID in the chronic setting.

Sponsors & Collaborators

  • FGK Clinical Research GmbH

    collaborator INDUSTRY

  • Liquidia Technologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Ardeschir Ghofrani, Prof. MD. · Universitatskinikum Giessen und Marburg GmbH

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-11
Primary Completion
2020-12-23
Completion
2020-12-23
FDA Drug
Yes

Countries

  • France
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03884465 on ClinicalTrials.gov